Back to News
Market Impact: 0.22
Oppenheimer Initiates Coverage of Collegium Pharmaceutical with Outperform
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Oppenheimer initiated coverage of Collegium Pharmaceutical (NASDAQGS: COLL) with an Outperform rating on September 23, 2026. The stock had closed at $22.78 on September 22; the favorable initiation is a modest positive catalyst but provides no stated price target or fundamental estimate revisions.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.28
Ticker Sentiment
COLL0.45
More News
- Street Calls of The Week
- argenx reports positive phase 3 data for autoimmune myositis drug
- Why the prognosis for healthcare stocks is uncertain ahead of Congress’ new makeup
- Top Wall Street analysts like these 3 dividend stocks for consistent income
- Crocs evp Rupert Campbell sells $399K of CROX stock
- MercadoLibre's Profits Fall Again. What It Means for Investors